Skip to main content
. 2020 Mar 18;20:29. doi: 10.1186/s12894-020-00601-w

Table 2.

Comparison of parameters between continence and incontinence patients at 1 and 3 months after operation

Variable 1 Month 3 Months
Continence (N = 264) Incontinence (N = 386) P value Continence (N = 396) Incontinence (N = 254) P value
Age (years) 65.60 ± 7.04 65.63 ± 7.94 0.959 65.20 ± 7.32 66.27 ± 7.94 0.080
BMI (kg/m2) 24.85 ± 2.75 25.14 ± 2.98 0.209 25.01 ± 2.82 25.02 ± 3.01 0.964
Comorbidities, no (%)
 HP 77 (29.17%) 141 (36.53%) 0.051 122 (30.81%) 96 (37.80%) 0.066
 DM 38 (14.39%) 77 (16.06%) 0.563 64 (16.16%) 36 (14.17%) 0.493
 CHD 20 (7.58%) 43 (11.14%) 0.131 38 (9.60%) 25 (9.84%) 0.917
 CD 9 (3.41%) 11 (2.85%) 0.685 10 (2.53%) 10 (3.94%) 0.309
 PSA (ng/mL) 27.65 ± 32.92 32.11 ± 36.08 0.109 28.65 ± 32.17 32.86 ± 38.64 0.133
 PV (mL) 37.73 ± 20.20 35.80 ± 18.58 0.211 37.15 ± 19.34 35.70 ± 19.15 0.348
 Gleason score, no (%) 0.475 0.654
 ≤6 79 (29.92%) 114 (29.53%) 117 (29.55%) 76 (29.92%)
 7 95 (35.98%) 160 (41.45%) 151 (38.13%) 104 (40.94%)
 ≥8 78 (29.55%) 97 (25.13%) 113 (28.54%) 62 (24.41%)
 Unknown 12 (4.55%) 15 (3.89%) 15 (3.78%) 12 (4.73%)
 Clinical T stage, no (%) 0.962 0.550
 T1a,b 1 (0.37%) 1 (0.26%) 1 (0.25%) 1 (0.39%)
 T1c 46 (17.42%) 68 (17.62%) 69 (17.42%) 45 (17.72%)
 T2a,b 102 (38.64%) 139 (36.01%) 157 (39.65%) 84 (33.07%)
 T2c 103 (39.02%) 155 (40.16%) 149 (37.63%) 109 (42.91%)
 T3a 1 (0.37%) 2 (0.51%) 1 (0.25%) 2 (0.79%)
 T3b 11 (4.17%) 21 (5.44%) 19 (4.80%) 13 (5.12%)
 OT (mins) 151.61 ± 42.16 153.81 ± 48.78 0.551 151.02 ± 41.76 155.86 ± 52.30 0.192
 NS, no (%) 73 (27.65%) 48 (12.44%) 0.000 87 (21.97%) 34 (13.39%) 0.045
 PLND, no (%) 121 (45.83%) 217 (56.22%) 0.009 204 (51.52%) 134 (52.76%) 0.757
 DIC (days) 21.22 ± 10.83 21.02 ± 10.09 0.810 21.28 ± 11.46 20.84 ± 8.46 0.601

Abbreviations: BMI Body mass index, CHD Coronary heart disease, CD Cerebrovascular diseases, DM Diabetes mellitus, DIC Duration of indwelling catheter, HP Hypertension, NS Nerve-sparing, OT Operation time, PSA Prostate-specific antigen, PV Prostate volume, PLND Pelvic lymph node dissection